Skip to main content
. 2019 Sep 11;33(12):2305–2312. doi: 10.1111/jdv.15862

Figure 4.

Figure 4

Proportion of patients with DLQI 0/1 from baseline to week 52 by week‐28 PASI response groups. (a) Patients continuously on tildrakizumab 100 mg from baseline to week 52. (b) Patients continuously on tildrakizumab 200 mg from baseline to week 52. DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; W, week.